Neofollin (Estradiol Valerate)

After intramuscular injection, estradiol valerate is converted to estradiol, the natural estrogen. The hormone binds to estrogen receptors in various tissues, activating gene transcription that restores estrogen‑dependent physiological functions such as bone maintenance, vasomotor regulation, and urogenital health.

The dosage of Neofollin is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s clinical condition, age, and response to therapy. No fixed regimen is provided in public literature.

Neofollin is generally reserved for women who are not pregnant. Use during pregnancy or lactation is only considered when the potential benefit outweighs the risk, and it should be decided by a healthcare professional after careful evaluation.

To request Neofollin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Neofollin delivers estradiol valerate as a depot injection, offering a longer duration of action compared with oral estradiol tablets that require daily dosing. This can improve adherence but requires intramuscular administration by a trained professional, whereas oral forms are self‑administered.

Neofollin should be stored refrigerated between 2 °C and 8 °C. Protect the vials from light, do not freeze, and avoid shaking. Keep the product in its original packaging until use to maintain stability.

Neofollin is given as an intramuscular injection, typically into the gluteal or deltoid muscle. Administration should be performed by a qualified healthcare professional using aseptic technique, following the dose prescribed by the treating physician.

Serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Additionally, there is a potential for endometrial hyperplasia or carcinoma, especially in women with pre‑existing estrogen‑dependent conditions.

Neofollin is contraindicated in women with known estrogen‑dependent tumors (e.g., breast or endometrial cancer), active or history of thromboembolic disease, uncontrolled hypertension, liver disease, or those who are pregnant unless clearly indicated by a physician.